The French firm mentioned the brand new ambition doesn’t embrace potential for extra gross sales ambition improve from persistent obstructive pulmonary illness, with readouts anticipated in 2023.
The corporate famous that by 2025, Dupixent is predicted to generate a further 11 new regulatory submissions throughout indications and age teams.
As well as, the corporate mentioned that it has 13 potential new medicines at present within the clinic to deal with persistent inflammatory illnesses, with 17 readouts anticipated by the top of 2024.
